Ceapro Inc - Company Profile
Powered by 
All the data and insights you need on Ceapro Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Ceapro Inc Strategy Report
- Understand Ceapro Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Ceapro Inc (Ceapro) is a biotechnology company that focuses on the development and commercialization of extracts and active ingredients from oats and other renewable plant resources. The company’s extracts are used in nutraceutical, cosmeceutical, and therapeutics products for personal, cosmetics, humans, and animals. Ceapro’s natural active ingredients include avenanthramides, oat beta glucan, oat oil, oat peptides, oat powder and lupin peptides; natural anti-aging skincare products, and veterinary products include ear cleanse, oat shampoo and dermal complex/conditioner. The company uses its proprietary Pressurized Gas eXpanded (PGX) technology for extraction of active ingredients. It markets its products through distribution partners, subsidiaries and directly to final consumers. The company offers products in Canada, the US, China, Germany, Japan, Europe, India, and other countries. Ceapro is headquartered in Edmonton, Alberta, Canada.
Headquarters
Canada
Address
7824 51 Ave Nw, Edmonton, Alberta, T6E6W2
Website
www.ceapro.com
Telephone
1 780 4214555
No of Employees
12
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
CZO (CVE)
Revenue (2021)
$14.5M
9.6%
(2021 vs 2020)
EPS
XYZ
Net Income (2021)
XYZ
30.7%
(2021 vs 2020)
Market Cap*
$13.8M
Net Profit Margin (2021)
XYZ
19.3%
(2021 vs 2020)
* As of and is in US$
Ceapro Inc premium industry data and analytics
Products and Services
| Products | Services |
|---|---|
| Natural Anti-Aging Skincare | Contract Manufacturing Services |
| Beta Glucan | |
| Avenanthramides | |
| XYZ | |
| XYZ | |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2024 | Regulatory Approval | In March, the company received approval from the Court of King's Bench of Alberta to merge with Aeterna Zentaris Inc. |
| 2023 | Plans/Strategy | In December, the company announced its plans to merge with Aeterna Zentaris Inc. |
| 2022 | Regulatory Approval | In November, the company received approval from Health Canada to commence Phase 1/2a human clinical trial assessing avenanthramide tablets. |
Competitor Comparison
| Key Parameters | Ceapro Inc | Medicamen Biotech Ltd | Microbix Biosystems Inc | Aptose Biosciences Inc | Eurofins Alphora |
|---|---|---|---|---|---|
| Headquarters | Canada | India | Canada | Canada | Canada |
| City | Edmonton | New Delhi | Mississauga | North York | Mississauga |
| State/Province | Alberta | Delhi | Ontario | Ontario | Ontario |
| No. of Employees | 12 | 388 | 69 | 35 | - |
| Entity Type | Public | Public | Public | Public | Private |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Ronnie Miller | Chairman | Executive Board | - | - |
| Gilles R. Gagnon | Chief Executive Officer; President; Director | Executive Board | - | - |
| Stacy Prefontaine | Chief Financial Officer | Senior Management | - | - |
| Sigrun Watson | Chief Revenue Officer | Senior Management | 2022 | - |
| Denis Bilodeau | Strategic Advisor | Senior Management | - | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer